INTRODUCTION
Acute vulvovaginal candidiasis is a common infection affecting up to 75% of sexually active women at some time during their reproductive life! and up to 50% of these will have at least one further episode'. Additionally, Candida spp can be isolated from the vagina in approximately 20% of asymptomatic women and may persist for months if not yearsv'.
There is an increased susceptibility to symptomatic vaginal infection and a higher prevalence of asymptomatic vaginal colonization among pregnant women, especiallyin the third trimester, and in those on the combined oral contraceptive pill with a high oestrogen content (50ILg)5,6 most likely due to a higher glycogen content in the vagina which provides a good source of nutrition for Candida spp', Although asymptomatic vaginal colonization with yeasts is more rommon among women with diabetes mellitus, particularly those who are insulindependent, symptomatic infection is unusual in the presence of good diabetic control-". Certainly, the commonest identified cause of acute vulvovaginal candidiasis follows the oral ingestion of broadspectrum antibiotics. Not only is there an increase in the prevalence of symptomatic candidiasis but higher rates of asymptomatic colonization, approaching 30%, have been reportedv". These effects are most likely due to the elimination of 'protective' bacteria, especially lactobacilli, which inhibit fungal colonization and germination of yeasts through mUlt~le factors which include competition for nutrients1 ,11. Infection is caused by yeast-like fungi of the Crupuxxxcaceae family of which C. albiams accounts for approximately 80% of clinical infections12,13. The remaining 20% are caused by Torulopsis glabrata or other Candida spp such as C. krusei, C. guilliermondi, C. tropicalis and C. pseudoiropicdis". The non-albicans Candida spp are known to be less responsive to conventional antifungal treatments than C. albicane'",
The adjacent perianal area is the source of yeasts which gain access to the vagina and, once there, may act as either commensal organisms or as pathogens depending upon environmental or host factors": Correspondence to: Dr 5 P Higgins Although no epithelial receptor has yet been identified, C. albicans is known to be capable of an adherence to vaginal cells which displays significant person to person variationl", while clinical vulvovaginal candidiasis is associated with a greater number of organisms than asymptomatic vaginal colonization, and the presence of germinated yeasts".
TOPICAL THERAPY
There are numerous topical pharmaceutical preparations availablefor the treatment of acute vulvovaginal candidiasis available as creams, pessaries and coated tampons. In an epidemiological study to determine the approaches to the management of candidiasis by physicians working in genitourinary clinics in England and Wales, and reported in 1979 16, topical nystatin was the commonest antifungal therapy prescribed, closely followed by topical clotrimazole. Miconazole was the third commonest topical antifungal prescribed. The polyenes, of which nystatin is the best known, have become less popular as firstline therapy principally because of the greater duration of therapy despite a clinical and m~cological response rate of between 70 and 80%1 ,18. In a study comparing a standard 14-day course of nystatin pessaries with a 3-day course of topical econazole nitrate it was found that both were equally efficacious in resolving symptoms and signs of infection with the added benefit of greater compliance with short-duration therapy and greater patient acceptability with the wax-like pessary base of econazoIe and reduced leakage; a common problem with nystatin pessaries which are dry, compressed tablets which, when dissolved, produce leakage in up to one-quarter of treated women!", Older agents, amongst which are included povidone iodine, boric acid and gentian violet no longer have a place as first-line agents.
Response rates of 80 to 90% can be expected with topical imidazoles when used over a period of up to 3 d ays20,21. Despite the multiplicity of treatment options (Table 1) no single agent appears to be significantly more efficacious than any other and selection should therefore be tailored to the individual patient's needs. The severity and duration of symptoms are likely to influence the success of treatment e.g. short-course regimens are less likely to be effective in severe cases. Pregnancy, a history of allergy, patient age, predicted compliance, and the cost of treatment may all influence treatment choice. Clotrimazole, one of the imidazoles, has emerged as the most commonly prescribed topical antifungal agent and has equal efficacy when §iven in a dosage of 100 mg for 6 consecutive days 2, 4 consecutive days23, as 200 mg once daily for 3 days24 or as a single 500 mg pessary (eradication rates between a single dose therapy and 3-day regimen are similar (94% versus 89%)p. Clotrimazole is fungicidal in vaginal secretions at a concentration of greater than 10JLg/ml and remains at this concentration for 72 h after insertion of a 500 mg pessary".
Miconazole persists for a long time in an active form in samples taken from the vagina at concentrations well within the normal range of minimum inhibitory concentration (MIC 0.01 to 2.0 JLg/ml) after a single 100 mg pessary'? and is still detectable in vaginal samples 2 days after insertion-". Miconazolecoated tampons are effective in the relief of symptoms, achieving a 93% mycological and clinical cure rate, provided they are used twice daily for at least 5 days-", This preparation may be more aesthetically acceptable to some patients than vaginal creams and/or pessaries.
Plasma imidazole levels after vaginal treatment are very low yet some have questioned their safety during pregnancy and, to this effect, the data sheet for isoconazole states that it should not be used during pregnancy. However, in view of the fetotoxicitycaused by imidazoles when given to pregnant rats, it is recommended that they should be used with caution during pregnancy, particularly in the first trimester. The onus is on the physician to decide that the benefits to the patient outweigh the risks to the fetus. Accordingly, it would seem sensible, when necessary, to treat pregnant women with a preparation such as clotrimazole which has been used in pregnancy for over 10 years without apparent ill effects.
Surveys in the mid-1980s indicated that many women would prefer oral to topical therapy, given the choice 30 • 31 • In one, much quoted study, just over half preferred oral formulations, 25% preferred topical creams, 14% hard pessaries and 10% soft pessaries-". In recent years, partly because of patient preference and poor compliance with intravaginal therapies, oral treatments have become increasingly popular.
ORAL THERAPY
The introduction in 1979 of the orally active agent ketoconazole was a noteworthy advance in antifungal therapy". Ketoconazole has to be taken over a period of several days and has a number of other disadvantages which include lack of selectivity, undesirable interactions with other therapeutic agents and interference with the synthesis and/or metabolism of endogenous steroids such as cortisol, ethinyl-oestradiol and testosterone 33 ,34. It is rapidly eliminated from the body and requires twice daily administration. Ketoconazole may increase the level of hepatic enzymes during therapy and hepatotoxicity has been estimated to occur in 0.1 to 1.0% of treated patients". Although it was the first oral preparation available, worries about hepatotoxicity, especially when used over prolonged periods, precluded its use in uncomplicated vulvovaginal candidiasis.
Fluconazole is an orally administered new generation triazole antifungal agent with reported activity against C. albicans and other Candida spp. Pharmacokinetic studies have shown that after a single oral dose of 150 mg, a therapeutic concentration is achieved in the vaginal tissues and secretions for at least 3 days, with a peak concentration in vaginal secretions occurring between 8 and 24 h after the dose and persisting longer in the plasma 36,37. Fluconazole appears to remain in the vaginal secretions for at least 7 days, although concentrations may be below the MIC for most Candida spp after 4 days. This may help to prevent relapse as well as eliminating the organisms from the deep vaginal tissue layers 36,37.
To date there have been 14 non-comparative and 14 comparative clinical studies involving fluconazole conducted in 19 different countries in Europe, Asia and Latin America. Between 1988 and 1991 there have been 2 non-comparative and 4 comparative clinical studies in the United Kingdom involving women with acute vulvovaginal candidiasis enrolled in the general practice setting. Three of these report 'cure rates' following the oral administration of fluconazole 150 mg (92%38, 84 39, and 71%40) while the remainder report 'clinical response rates' (92%41, 99%42, and 94.7%43) without defining the degree of clinical response. In each study great emphasis was placed on 'mycological cure rates' with frequent reference to the patient's preference for oral therapy.
Fluconazole is well tolerated and relatively safe. Unwanted side effects are mild and usually related to the gastrointestinal tract, consisting most commonly of nausea and abdominal pain. Occasionally, abnormal liver function tests have been noted in otherwise healthy individuals and consequently fluconazole should be used with caution in those known to have hepatic disease. As with all triazoles, therapy is contraindicated during pregnancy.
In contrast to fluconazole which is water soluble, itraconazole (another triazole) is highly lipophilic and has a selective preference for keratinized tissues, in particular skin. Tissue levels of itraconazole can be up to 5 times higher than corresponding plasma levelsvt, while kinetic studies have shown that drug levels in vaginal tissue remain at therapeutic concentrations for at least 2 days after the end of therapy'".
There is a paucity of published clinical trials of itraconazole in the United Kingdom. Clinical cure rates of 70 to 81% with mycological cure rates of 71 to 81% at one week follow-up have been reported 4O,44,46-48. Several different regimens of administration of itraconazole have been investigated including 200 mg daily for 2 consecutive days, 200 mg daily for 3 consecutive days, and 200 mg twice daily for one day, and found that the difference in length of therapy played no s~nificant role in determining the final cure rate 49-.
Intraconazole is given at a dose of 200 mg twice daily for one day and should be taken after meals for maximum absorption. The incidence of adverse events, usually gastrointestinal, are mild and there have been no reports of abnormal serum biochemical or haematological indices after treatment 51,52. A major advantage of itraconazole over fluconazole is its broader spectrum of activity as it is particularly active against Torulopsis glabrata which is second only to C. albicans in frequency of isolation from the vagina in women with yeast vaginitis 53.
CHOICE OF THERAPY
The literature of comparative clinical trials is not extensive yet most frequently oral therapy is compared with the most commonly used topical agent-clotrimazole. Two comparative studies of single dose oral fluconazole (50 mg39 and 150 mg41 ) with 3-day intravaginal clotrimazole (200 mg) showed that both oral and topical therapies were equally effective in the treatment of acute vulvovaginal candidiasis. Similarly, a comparative study of the efficacy of oral itraconazole (200 mg twice daily for one day) with a Single intravaginal clotrimazole (500 mg) pessary found both to be equally effective in establishing a mycological cure".
There is but a single study comparing fluconazole with itraconazolew. In this single-blind, randomized trial, 306 women with acute vulvovaginal candidiasis received fluconazole (150 mg) and 317 itraconazole (200 mg twice daily). At short-term (5-16 days) and long-term (28 days) follow-up there was no significant difference in the numbers of women symptomatically cured or improved in each treatment group (fluconazole 94% versus itraconazole 93%). The recurrence rate was equal in both groups (10%).
Among the multiplicity of topical therapies, clotrimazole pessaries and cream have emerged as the most widely used treatment. Topical therapy has remained first-line treatment despite the introduction of the newer oral antifungal agents, fluconazole and itraconazole. Severe, extensive inflammation is less likely to respond to single dose therapy and prolonged topical therapy is more likely to achieve complete resolution of symptoms and signs. Occasionally the addition of a topical steroid may be required to control such episodes but their routine use is to be avoided. In the presence of severe inflammation patients should be warned that they may experience a local burning sensation following the topical application of imidazoles which is most often an irritant reaction to the vehicle used rather than the antimycotic.
There are clinical situations in which oral therapy is to be preferred over topical therapy e.g. hypersensitivity to irnidazoles, first-episode genital herpes or a severe episode of recurrent genital herpes in which there is co-existent fungal infection.
It has been shown that many women prefer oral therapy (49%) to vaginal therapy (5%) 54 and patient preference should be taken into account when prescribing antifungal treatment. There are some women who find vaginal therapy abhorrent and should not be denied oral therapy as first-line treatment.
At present in the United Kingdom perhaps the single most important reason for oral agents being used as second rather than first-line treatment in acute vulvovaginal candidiasis is their higher cost compared with the standard topical therapies.
